TRPA1 and depressive symptom measurement: Moreover, it is known that TRPA1 agonists in the hippocampus lead to the depressive-and anxiolytic-like effects, while pharmacological blockage or TRPA1 gene deletion reduce the depression-and anxiolytic-like symptoms.